Ascendis Pharma A/S
ASND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $364 | $267 | $51 | $8 |
| % Growth | 36.3% | 421.2% | 557.9% | – |
| Cost of Goods Sold | $44 | $44 | $12 | $4 |
| Gross Profit | $319 | $222 | $39 | $4 |
| % Margin | 87.8% | 83.4% | 76.3% | 54.7% |
| R&D Expenses | $307 | $413 | $380 | $296 |
| G&A Expenses | $285 | $259 | $216 | $0 |
| SG&A Expenses | $285 | $259 | $216 | $160 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $7 | $6 | $5 | $0 |
| Operating Expenses | $598 | $678 | $601 | $456 |
| Operating Income | -$279 | -$456 | -$562 | -$452 |
| % Margin | -76.7% | -170.8% | -1,097.9% | -5,808.6% |
| Other Income/Exp. Net | -$94 | -$19 | -$16 | $68 |
| Pre-Tax Income | -$373 | -$474 | -$578 | -$384 |
| Tax Expense | $5 | $7 | $5 | -$0 |
| Net Income | -$378 | -$481 | -$583 | -$384 |
| % Margin | -104% | -180.5% | -1,139.6% | -4,931.6% |
| EPS | -6.53 | -8.55 | -10.4 | -7 |
| % Growth | 23.6% | 17.8% | -48.6% | – |
| EPS Diluted | -6.53 | -8.55 | -10.4 | -7 |
| Weighted Avg Shares Out | 58 | 56 | 56 | 55 |
| Weighted Avg Shares Out Dil | 58 | 56 | 56 | 55 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $17 | $7 | $1 |
| Interest Expense | $66 | $44 | $31 | $4 |
| Depreciation & Amortization | $18 | $19 | $18 | $15 |
| EBITDA | -$290 | -$411 | -$529 | -$365 |
| % Margin | -79.8% | -154.2% | -1,034.1% | -4,688.1% |